- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07399678
Estudio de ALV-100 para evaluar la seguridad, tolerabilidad y PK/PD en participantes con sobrepeso/obesidad con o sin T2D
Un estudio de Fase 1b, aleatorizado, doble ciego, controlado con placebo y de escalada de dosis que evalúa la seguridad, tolerabilidad, farmacocinética y farmacodinámica de ALV-100 en participantes con sobrepeso u obesidad con o sin diabetes tipo 2
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Miami, Florida, Estados Unidos, 33172
- Clinical Pharmacology of Miami
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43212
- Ohio Clinical Trials
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78240
- Endeavor Clinical Trials
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
For Part A and B
- Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
- Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
- Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
- Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
- Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.
For Part B only
- Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
- Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
- Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.
Exclusion Criteria:
For Part A and B
- History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
- Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
- Current or history of chronic or acute pancreatitis.
- Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
- History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
- Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
- Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
- History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.
Part A only
• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).
Part B only
- Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
- Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
- Severe neuropathy as judged by the investigator.
- Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
- History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part A - Cohort 1 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Comparador de placebos: Part A - Cohort 1 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part A - Cohort 2 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Comparador de placebos: Part A - Cohort 2 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part A - Cohort 3 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Comparador de placebos: Part A - Cohort 3 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part A - Cohort 4 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Comparador de placebos: Part A - Cohort 4 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimental: Part B - T2D Cohort (ALV-100)
Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Comparador de placebos: Part B - T2D Cohort (Placebo)
Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and tolerability
Periodo de tiempo: From First Dose to Week 52
|
Incidence of treatment emergent adverse events (TEAEs) |
From First Dose to Week 52
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - Cmax, MD
Periodo de tiempo: From First Dose to Week 52
|
Maximum observed serum concentration after multiple doses (MD) (Cmax, MD) |
From First Dose to Week 52
|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - AUC(0-τ), MD
Periodo de tiempo: From First Dose to Week 52
|
Area under the serum concentration-time curve from time zero to τ, where τ is the dosing interval, (AUC(0-τ), MD) |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact on body weight
Periodo de tiempo: Baseline, Week 32 and Week 52
|
Change from baseline in body weight |
Baseline, Week 32 and Week 52
|
|
Pharmacodynamic (PD) impact on body weight percentage
Periodo de tiempo: Baseline, Week 32 and Week 52
|
Change from baseline in body weight percentage |
Baseline, Week 32 and Week 52
|
|
Immunogenicity
Periodo de tiempo: From Baseline to Week 52
|
Incidence of Anti-ALV-100 drug antibodies, including assessments of cross-reactivity and neutralizing antibodies. |
From Baseline to Week 52
|
|
Relationship between ALV-100 serum concentration and QTc interval changes (Part A Only)
Periodo de tiempo: From First Dose to Week 52
|
Measurement of change in individual specific heart rate corrected QT interval (QTcI) and Fridericia heart rate corrected QT interval (QTcF) on 12-lead ECG. |
From First Dose to Week 52
|
|
Paracetamol (acetaminophen) absorption test (PAT) (Part A Only)
Periodo de tiempo: From First Dose to Week 52
|
Measurement of acetaminophen PK parameters to evaluate the effect of ALV-100 on the gastric emptying rate. |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact of ALV-100 on antidiabetic medication (Part B Only)
Periodo de tiempo: From Baseline to Week 32
|
Change in use of concomitant glucose-lowering medication |
From Baseline to Week 32
|
|
Pharmacodynamic (PD) impact of ALV-100 on glycemic parameters (Part B Only)
Periodo de tiempo: Week 32 and Week 52
|
Measuring the number of participants achieving target Hemoglobin A1c values |
Week 32 and Week 52
|
|
Hypoglycemic Safety (Part B Only)
Periodo de tiempo: From Baseline to Week 52
|
Measured by the incidence of symptomatic hypoglycemia, documented symptomatic hypoglycemia and severe hypoglycemia |
From Baseline to Week 52
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Karen Tornøe, MD, PhD, Alveus Therapeutics
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Trastornos Nutricionales
- Enfermedades metabólicas
- Sobrenutrición
- Peso corporal
- Cambios en el peso corporal
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Signos y síntomas
- Exceso de peso
- Obesidad
- Pérdida de peso
- Diabetes Mellitus, Tipo 2
Otros números de identificación del estudio
- ALV-102-1
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .